Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Antiproliferative and cytotoxic effects of aplidine assessed in human cancer cell lines

Dec. 3, 2003

Preclinical and clinical antitumor efficacy and clinical safety of Bay-43-9006

Dec. 3, 2003

Radiosensitizing effects of GW-572016 and use in combination chemotherapy

Dec. 3, 2003

Antitumor effects of irofulven in advanced cancer

Dec. 3, 2003

Antitumor effects of TZT-1027 in advanced cancer patients

Dec. 2, 2003

Efficacy and tolerance of MS-275 in patients with refractory tumors

Dec. 2, 2003

Progression-free survival prolonged in Avastin study in colorectal cancer

Dec. 1, 2003

Enrollment completed in STELLAR 3 pivotal trial of Xyotax

Dec. 1, 2003

Antiangiogenic and antiproliferative effects described for AP-23573 in tumor cells

Dec. 1, 2003

Plenaxis receives FDA approval

Nov. 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...